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SUMMARY
Ribavirin is used in the treatment of respiratory paramyxovirus infection in
lung transplant recipients; however, its pharmacokinetic profile in the
transplant population is unknown despite the potential for alterations due to
underlying pathology. Furthermore, the ability of current regimens to meet
exposure targets has not been established. This study examined the
pharmacokinetics of ribavirin in a lung transplant population from which
current and alternate dosing regimens were assessed. Population
pharmacokinetic modelling was conducted in NONMEM using concentrationtime data from 24 lung transplant recipients and 6 healthy volunteers. Monte
Carlo simulation was used to assess the ability of dosing regimens to achieve
pre-specified target concentrations. A three-compartment model with first
order elimination most adequately described ribavirin concentration-time data,
with creatinine clearance and patient type (i.e. lung transplant) identified as
significant covariates in the model. Simulations indicate that current regimens
achieve efficacious concentrations within 24 hours of treatment initiation that
increase to supra-therapeutic levels over the treatment period. A regimen of 8
mg/kg q6h oral for 48 hours followed by 8 mg/kg q24h oral for the remainder of
the treatment period was predicted to result in >90% of patients exhibiting
concentrations within the defined target range throughout the entire treatment
course. Additional work to formally establish of target therapeutic
concentrations is required; however, this study provides a valuable first step in
determining optimal ribavirin treatment regimens for paramyxovirus infections
in the lung transplant population.
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PREFACE
This project was a joint undertaking between St Vincent’s Hospital Sydney and
the University Medical Centre Groningen, both of which are thoracic transplant
centres with established research programs aimed at increasing median
survival in solid organ transplant recipients. St Vincent’s Hospital Sydney has
been a globally recognised centre for excellence in the field of heart and lung
transplant since 1987. The Department of Thoracic Medicine has performed
over 870 lung transplant procedures since it opened and currently performs
over 50 transplants annually. As a global leader in thoracic transplantation the
necessity of a multi-disciplinary approach in achieving good outcomes in
transplant recipients is well understood. This includes a close working
relationship between the Department of Thoracic Medicine and the Department
of Infectious Diseases. Infections of all types are a major factor in reduced
survival post-transplant due to both acute morbidity and mortality in
immunosuppressed patients as well as the immunomodulatory effect of
immune/pathogen interface on long-term graft tolerance

1,2,9,10,12,13

Investigation into

effective antimicrobial therapies for transplant patients is a primary focus of
transplant medicine both at St Vincent’s, Groningen and globally.
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CHAPTER 1: Introduction
Ribavirin is a guanosine analogue antiviral agent used for the treatment of
community acquired respiratory viruses including respiratory syncytial virus
(RSV), human metapneumovirus (HMPV) and parainfluenza virus in lung
transplant recipients. Ribavirin was licensed for use in 1986 for aerosolised
treatment of RSV in infants and the oral formulation was approved for
treatment of hepatitis C in 1998, but it has a broad spectrum of activity against
DNA and RNA viruses. Until recently the main indication for ribavirin was
hepatitis C infection. However with the introduction of direct-acting-antiviral
agents ribavirin’s primary utility is now respiratory infection in
immunosuppressed patients. Goals of treatment are both to prevent acute
1-7

progression to pneumonitis and to reduce the incidence of infection associated
bronchiolitis obliterans syndrome (BOS). Although historical studies have
5,6

focused on the efficacy of aerosolised ribavirin, transplant centres now use both
intravenous and oral regimes to avoid airborne drug exposure and resultant
toxicity to health care staff.

10-14

Data from studies on lung transplant recipients conducted at St Vincent’s
Hospital in Sydney support the use of intravenous and oral ribavirin in the
treatment of RSV. However, there is no data on the pharmacokinetics of
14

ribavirin in the transplant population, nor comparison regarding therapeutic
serum concentrations between different routes of drug administration. Studies
from hepatitis C infected patients have been used to establish the safe
therapeutic index for ribavirin using the haemoglobin level as a marker of
toxicity; however, this data is based on a prolonged oral course of up to six
months duration.

15-17,20

Ribavirin is a drug with a long terminal half-life that

accumulates in red blood cells, the toxicity therefore may not be similar in short
term use, even with identical plasma concentrations. RSV and HMPV have been
shown to have an IC50 estimated at 1.35 – 5.82 mg/L in vitro.

15-17,20

However, to

date, effective short-term dosing strategies for achievement of viral inhibition
have not been established in the clinical setting. Current treatment strategies
typically comprise a loading dose of 11 mg/kg TDS for the first 24 hours of
treatment, followed by a maintenance dose of 10 mg/kg BD with the
assumption that maximum time at the highest tolerated plasma concentration
will most effectively inhibit viral replication.
Page|9

It is feasible that transplant recipients as a population may manifest deviations
in the pharmacokinetic profile of antimicrobial agents and other drugs due to
physiological changes induced by the transplant and subsequent
immunosuppressive therapy. Such changes may include: a high incidence of
impaired renal function, polypharmacy from immunosuppressive regimens
and multiple other routine medications, and heavy corticosteroid exposure with
associated alterations in hepatic metabolism. In cystic fibrosis (CF) patients,
drug metabolism is altered by abnormal gastrointestinal absorption. Total body
fat content and stomach contents also influence the absorption and distribution
of ribavirin which may be an issue even in non-CF transplant recipients as the
prevalence of malnutrition is high in this population.

15-17,20

Effective treatment for viral respiratory infection in lung transplant recipients is
crucial. However, for the reasons outlined, knowledge regarding effective
treatment protocols is lacking. A thorough investigation of the
pharmacokinetics of ribavirin in this patient population is required from which
effective treatment strategies can be assessed and devised. Initially a review of
the literature was undertaken to elicit gaps in the field.

LITERATURE REVIEW
Data Sources
Databases MEDLINE, PubMed and EMBASE were searched using the terms;
“ribavirin”, “respiratory syncytial virus” or “RSV” and “toxicity” and/or
“therapeutic window/index” and/or “serum concentration” and/or
“pharmacokinetic*”. The Cochrane database was also searched with the same
terms.
Publication Selection and Data Extraction
All relevant original studies, meta-analyses, systematic reviews, case-series and
case-studies were assessed for inclusion. Reviews and general discussion of
community acquired respiratory viruses were not included unless they had
specific focus on RSV/HMPV or ribavirin treatment. Reference articles were
included if they contained relevant information. Articles that focused
exclusively on stem-cell transplantation or immunocompetent paediatric
P a g e | 10

populations were not included as results from these were not thought to be
generalisable to the solid organ transplant population.
Search Results
A search of the Medline database returned a total of 100 articles. The further
specifications “English language” and “human” were added reducing the total
to 85 articles. Of these 85, 47 were instantly excluded as irrelevant to the topic.
A further 17 articles were excluded for being specific only to the
immunocompetent paediatric population. A further seven articles were
excluded for pertaining specifically to use of ribavirin in the context of stem cell
transplant patients. A total of 21 articles from the Medline search were
included.
An EMBASE search using the exploded terms “ ribavirin“, “respiratory
syncytial virus“ and “ transplant“ also returned 85 results. Of these, 60 were
immediately excluded as irrelevant to the scope of this enquiry. Of the 25
included, an additional four were excluded as duplicated from the Medline
search.
A search of the Cochrane database returned two meta-analyses, both pertaining
to an immunocompetent paediatric population. These were not included.
Respiratory Syncytial Virus and the Human Metapneumovirus
The threat of community acquired respiratory viruses to transplanted lungs is
well described.

21-23

RSV and HMPV cause a spectrum of illness ranging from mild

respiratory symptoms to severe lower respiratory tract infections including
bronchiolitis, pneumonia and respiratory failure, with a mortality of 10-20%.

24,25

In the setting of lung transplantation, RSV infection has been associated with
the development of bronchiolitis obliterans and long-term, irreversible loss of
lung function with reduced survival. Current evidence suggests ribavirin
reduces the incidence of BOS and the duration of symptoms in lung transplant
patients.

6,10-14,21-23

Small case control studies also suggest non-inferiority of oral

ribavirin in comparison with intravenous administration for RSV treatment.

5,6,10,12-14

HMPV produces similar pathology to RSV and has been estimated to be the
25

cause of viral respiratory tract infection in up to 4% of hospitalised adults in the
P a g e | 11

United States. HMPV is usually a mild self-limiting illness in the general
27

population but causes more serious illness in the immunosuppressed
population. RSV is implicated in the development of BOS along with other
community acquired respiratory viruses.

Bronchiolitis Obliterans Syndrome
BOS refers to a syndrome of progressive, irreversible airway destruction that
afflicts lung transplant recipients. Exact rates of BOS are difficult to determine
28

due to the difficulty of recruiting large cohorts of transplant recipients for
study. However, the largest experience, from the International Society for Heart
and Lung Transplant (ISHLT) registry, reports that 48% of recipients develop
BOS by five years after lung transplant and 76% develop BOS after ten years.

29

Risk factors for BOS are manyfold. Besides viral infections, other factors that
increase BOS risk include episodes of acute immune-mediated organ rejection,
bacterial and fungal colonisation, primary graft dysfunction and
gastroesophageal reflux disease. Single (rather than double) lung transplant
procedure also increases BOS risk. There are emergent theories regarding the
28

pathobiology of BOS. It is postulated that BOS could result from autoimmunity
(in addition to allo-immunity) to the usually hidden sub-epithelial collagen type
V epitopes. These epitopes become exposed during inflammation from infection
or due to ischemia, or vascular reperfusion injury during the transplant
procedure. Moreover, increasing evidence suggests that patients with pre30

existing antibodies to Human Leucocyte Antigen (HLA) or Major
Histocompatibility Complex (MHC) Class I chain-related gene A antigens are at
a higher risk of developing BOS after transplantation.

31

At present no effective evidence-based treatment for BOS is available; the only
treatment option is prevention. Severity is based on radiological assessment and
ongoing and regular FEV1 measurement in transplant clinics. BOS severity is
ranked via a validated international scoring system. The ultimate consequence
of BOS is graft failure and death except in the very rare instance of a second
transplant.

P a g e | 12

Clinical Management of RSV Pneumonitis
Oral, intravenous and aerosolised ribavirin have all been administered for RSV
infection in lung transplant recipients and other vulnerable populations. There
is data supporting the efficacy of all forms of ribavirin for the treatment of RSV
pneumonitis in lung transplant recipients. A double-blind trial of placebo
1-7

versus aerosolised ribavirin on 16 otherwise healthy young adults voluntarily
exposed to RSV (and displaying symptoms of respiratory infection)
demonstrated diminished viral shedding and a reduced incidence of systemic
complaints such as fever and malaise. However, it is notable that it did not have
any impact on resolution of respiratory symptoms. Lewis et. al. examined
32

aerosolised ribavirin for efficacy against RSV and parainfluenza virus in a
cohort of fifteen lung transplant recipients. Only a third of these patients were
treated with ribavirin and the results were equivocal. This study also suggests
33

underlying pulmonary fibrosis may be an independent risk factor for worse
long-term outcomes despite successful treatment of RSV. However, it could be
suggested that patients with pulmonary fibrosis are likely to have less baseline
pulmonary reserve. Hynicka and Ensor recommend aerosolised ribavirin as
part of a combination antiviral/immunomodulator regime for efficacious
treatment of RSV infection. Additionally, studies by Kwak and colleagues and
34

Li et. al demonstrated no significant difference in outcomes for oral versus
inhaled ribavirin therapy in the context of RSV infection.

35,36

These studies also

demonstrated a reduction in dyspnoea and the incidence of BOS after
treatment with ribavirin. Kwak notes patients receiving oral ribavirin tended to
stay in hospital for longer. However this may be a coincidental correlation as
35

this study had a cohort of only six patients.
Ribavirin Pharmacology
Ribavirin is characterised by multi-compartmental pharmacokinetics with
broad distribution into all tissues and a characteristic long terminal half-life. It
is a prodrug which is quickly phosphorylated into its active form after crossing
the cell membrane via the ubiquitous es transporter. However, once
phosphorylated it can no longer exit the red cell in the same manner,
accounting for the drug’s accumulation in erythrocytes and other cells without
dephosphorylating enzymes. Approximately 85% of ribavirin is converted into
15

a triphosphate form with the remaining 15% monophosphate or diphosphate
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ribavirin molecules. It is postulated that the monophosphate form may be
15

more active against RSV.
The mechanism of anti-viral action is not fully understood, however proposed
mechanisms include critical depletion of available guanosine triphosphate
(GTP) required for viral DNA/RNA replication. Additionally, the
monophosphate form is known to completely inhibit inosine-5’monophosphate dehydrogenase, an enzyme that cleaves GTP. This mechanism
is likely to be most effective in inhibiting paramyxovirus production due to the
specific viral replication methods. Ribavirin has also been observed to have
immunomodulatory effects on CD4+ cytokine production although this is
probably more relevant to the action against hepatitis C.

15,37-43

The anti-viral effect

of ribavirin is dependent on dosage and resultant plasma concentrations of the
drug; thus understanding the pharmacokinetic properties are critical to the
identification of optimal treatment protocols.
Ribavirin Therapeutics
Oral, intravenous and aerosolised ribavirin have all been employed in the
treatment of RSV infection; however, evidence for effective plasma
concentrations is lacking. Concentrations required to inhibit RSV replication by
50% (IC ) have been estimated at 1.35 – 5.82 mg/L in vitro, with similar values
50

for HMPV. Previously publishes reasearch has indicated that effective
concentrations are >2.5 mg/L; however, given the known association between
plasma concentrations >3.5 mg/L and haemolytic anaemia, a target therapeutic
range of 2.5 – 3.0 mg/L is suggested with outer limits of 1.5 – 4.0 mg/L.

44- 47

This

therapeutic window has been based on observation of patients treated for
hepatitis C.

44- 47

As well as the previously discussed dose-associated haemolytic anaemia,
ribavirin has been demonstrated to increase the risk of myocardial infarction in
patients with pre-existing cardiac disease.

15,48

ribavirin has teratogenic qualities

and should not be given to pregnant women or males with pregnant partners.

48

Avoidance of conception is advised for six months after drug exposure which
presents particular administration difficulties for health care workers and has
resulted in reduced use of the aerosolized form to avoid passive exposure for
hospital staff.
P a g e | 14

Local protocols for treatment of respiratory viruses with ribavirin differ in
international centres. This is due to the lack of definitive evidence on superior
dosing strategies. Ribavirin’s use as an agent for RSV treatment originated in
the 1980s, when the aerosolised form, administered inside containment tents on
paediatric wards, was recommended for paediatric RSV pneumonitis.
However, lack of supporting clinical trials and significant associated toxicity for
both patients and health care workers using the drug’s aerosolised form lead to
the American Academy of Paediatrics withdrawing this recommendation in the
early 2000s. In adult patients, ribavirin was extrapolated from its previous
[22]

paediatric use as a treatment for RSV and other viral causes of pneumonitis and
has shown benefit in case series and small cohort studies of
immunocompromised patients being treated for RSB in in both PO and IV
preperations.

. However, despite common clinical use, the ability of current

12,21,22]

dosing regimens to meet suggested therapeutic targets is unclear, particularly
given the notable physiological differences between solid organ transplant
recipients and the general population (with likely to impact on
pharmacokinetics). Research to determine ribavirin pharmacokinetics in the
lung transplant population and examine the ability of current and alternate
dosing regimens to meet the pre-defined therapeutic target is needed.
Aims and Objectives
The aim of this project was to establish the pharmacokinetic profile of ribavirin
in lung transplant recipients and to examine dosing strategies to optimise the
attainment of target concentrations.
The project was designed to use a population pharmacokinetic approach to
address several questions within the scope of the project including, but not
limited to:
•

Is there a difference between the pharmacokinetics of ribavirin in lung
transplant recipients when compared with healthy volunteers?

•

Do current dosing strategies reach or exceed the currently accepted safe
and effective therapeutic window?

•

Do current dosing strategies maintain patients in an effective therapeutic
window for the duration of treatment?
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•

Are there alternative dosing regimens that would better maintain
patients at effective plasma concentration for the duration of therapy?

•

Is an intravenous loading dose necessary to reach an effective plasma
concentration?

Although this was not the primary objective of this particular study, it was
envisaged that the developed population pharmacokinetic model could be used
for additional work to examine more complex dosing strategies such as
opportunities for therapeutic drug monitoring in which dosing would not just
be based on generalised population data but personalised for the individual
patient.

P a g e | 16

CHAPTER 2: Methodology
The study comprised a combined prospective and retrospective analysis of realtime pharmacokinetic data from cohorts across two international centres, as
well as the inclusion of previously-published ribavirin intensive concentrationtime data from healthy volunteers.

ETHICAL CONSIDERATIONS
The study protocols at both clinical centres were reviewed and approved by the
respective institutional Human Research Ethics Committees (St Vincent’s
Hospital Sydney Human Research Ethics Committee HREC/15/SVH/74 and
Medisch Ethische Toetsingscommissie University Medical Center Groningen
METc 2015/452).
Participants from the prospective (Australian) cohort were recruited via the
Lung Transplant Clinic at St Vincent’s Hospital. Each study participant was
fully informed of the study procedures and was provided with a written
information sheet detailing the nature of the study prior to study recruitment.
The retrospective cohort (at University Medical Centre Groningen) were not
provided with written information as their protocol did not deviate from
standard of care. Informed patient consent was obtained under the direction of
the UNMCG ethics committee.
The project in entirety was conducted in accordance with the study protocols as
approved by the ethics committees and the Declaration of Helsinki.

ELIGIBILITY CRITERIA
To be deemed eligible for study inclusion, potential participants were required
to be over 18 years of age, a lung transplant recipient and requiring ribavirin
treatment for viral infection. Patients undergoing haemodialysis were excluded
from participation. History of previous RSV or respiratory viral infection was
not a factor considered in determining eligibility. All levels of severity of
infection were accepted into the study including patients admitted to the
intensive care unit. No formal restrictions on time since transplantation were
included as part of the eligibility criteria, but all patients were required to be
P a g e | 17

stable since receipt of transplant and not have been transplanted for acute viral
pneumonitis.

STUDY PROCEDURES
St Vincent's Hospital
As per standard practice, lung transplant patients who test positive for RSV on
qualitative nasopharyngeal swab polymerase chain reaction (PCR) are
prescribed a mixed intravenous and oral ribavirin regimen comprising a
loading dose of 11 mg/kg TDS IV as a 30-minute infusion for the first 24 hours
followed by a maintenance dose of 10 mg/kg BD PO for up to 14 days
depending on the duration of clinical symptoms. Clearance swabs are not
performed due to the lack of availability of quantitative RSV PCR.
Nasopharyngeal swabs remain positive for RSV and HMPV some weeks after
resolution of the viral illness due to persistent fragments of dead virus in the
airways. ribavirin plasma concentration testing is not performed routinely in
this clinical setting.
Upon identification of a suitable patient for study recruitment, the registrar on
call for lung transplant patient admissions would alert the study investigator.
The study investigator would then assess the patient’s suitability for the study,
explain the study protocol and goals to the patient and obtain written consent.
Study participants were administered a mixed IV and PO ribavirin dosing
regimen as per standard practice. Blood samples for analysis of plasma
ribavirin concentrations were collected by the study investigator via
venepuncture at various times after dose administration with a rich sampling
strategy; the first sample was collected immediately prior to the first dose
administration and then at 0.5 hours (after completion of the infusion) and 1, 2,
3, 4, 6 and 8 hours after the start of the infusion. Additional samples were also
collected on the morning of Day 4 and Day 7 of treatment immediately prior to
the scheduled oral dose and then 2 hours after dose administration.
Due to the logistic difficulties in performing plasma analysis immediately after
blood collection a protocol was developed for samples to be centrifuged and
separated by the venepuncturist, then frozen to be assayed within working
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hours. All investigators were trained in sample preparation by a senior scientist
from the Clinical Pharmacology laboratory.
University Medical Centre Groningen
Patients with RSV or HMPV infection are routinely treated with oral ribavirin
administered as a loading dose of 11 mg/kg TDS PO for the first 24 hours,
followed by a maintenance dose of 10 mg/kg BD PO. Standard of care includes
monitoring of plasma ribavirin concentrations at 1.5 hours after administration
of the first dose and then immediately prior to morning dose administration on
Day 2, 4, 7 and 10. Nasopharyngeal swabs for clearance are not routinely
performed.
Study participants were identified from review of patient medical records and
data collected retrospectively by the project collaborators.
Biological Sample Analysis
Blood samples were centrifuged immediately after collection, aliquoted for
storage and frozen at -20°C for sample stability until ribavirin concentration
analysis could occur. Plasma samples were analysed for ribavirin
concentrations on dedicated equipment in the Department of Clinical
Pharmacology and Toxicology, St Vincent’s Hospital and the Department of
Clinical Pharmacy and Pharmacology, University Medical Centre Groningen
using validated Liquid Chromatography Tandem Mass Spectrometry
methodology.

53

Values for samples returning concentrations below the lower limit of
quantification of the assay were not made available by the analytical laboratory;
these samples were excluded from the pharmacokinetic dataset.
Healthy Volunteer Dataset
Additional data for the development of the population pharmacokinetic model
was extracted from previously published work examining the pharmacokinetics
of oral and intravenous ribavirin in healthy normal volunteers. Participants in
8

this study were administered single doses of 150 mg ribavirin IV and 400 mg
ribavirin PO. Blood samples were collected immediately prior to dosing and
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then 0.083, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 7, 9, 11, 13, 17, 25, 37, 49, 61,
73, 97, 121, 145 and 169 hours after dosing.
Concentration-time data was extracted using Engauge Digitizer software
(http://markummitchell.github.io/engauge-digitizer).

POPULATION PHARMACOKINETIC MODELLING
Model Development
Population pharmacokinetic modelling and simulation was conducted using
NONMEM® VII (ICON Development Solutions, Ellicott City, MD, USA)
software with an Intel Fortran complier and Wings for NONMEM interface
(http://wfn.sourceforge.net).
One-, two- and three-compartment models with first-order absorption and
elimination from the central compartment were fitted to plasma ribavirin
concentration-time data. Models with absorption lag time were screened to
account for any time delay between administration and the beginning of drug
absorption. In addition, more complex absorption models based on a chain of
absorption transit compartments were also investigated. The pharmacokinetic
models were parameterised (where appropriate) as clearance (CL), volume of
distribution of the central compartment (Vc), inter-compartmental clearance(s)
(CLd), volume of distribution of the peripheral compartment(s) (Vp),
absorption rate constant (Ka), absorption lag time (Alag) and bioavailability (F).
The model incorporated population parameter variability (comprising betweensubject and between-occasion variability) and residual unexplained variability
(comprising proportional and/or additive error).
Once the base structural model had been determined, the contributions of
continuous (age, body weight, renal function) and categorical (gender, patient
type) covariates to population parameter variability were assessed using a
forward selection – backward elimination procedure.
Model selection was based on the objective function value (minus twice the loglikelihood of the data) as well as visual inspection of the standard diagnostic
plots. A statistically significant (p<0.05) improvement in the comparison of
P a g e | 20

nested models was defined as a decrease in the objective function value of 3.84
U (for 1 degree of freedom). The final population pharmacokinetic model was
evaluated through visual predictive checks.
The population pharmacokinetic model was developed and evaluated in
consultation with Dr Reuter Lange. Full details of the model development are
contained within Appendix 1.
Monte Carlo Simulation
To assess the ability of current and alternate dosing regimens to meet target
ribavirin concentrations over a 14-day treatment course, the final population
pharmacokinetic model was used to simulate datasets for a representative
patient population of 10,000 individuals. Model simulation was conducted
using R Version 3.3.2 (R Foundation for Statistical Computing).
®

CHANGES TO STUDY PROTOCOL
At the St Vincent's Hospital study site, rigorous adherence to the sampling
protocol proved logistically impossible for several reasons including staff
resources and patient preferences about sample collection timing. Additionally,
sample collection often had to be negotiated around other clinical commitments
for study investigators. Many patients expressed that the burden of clinic visits
is heavy for transplant recipients and they would prefer not to present to the
hospital for a blood-collection for the benefit of research alone. In response to
this logistical difficulty a policy of sampling as intensely as possible within the
available timeframe was adopted. This allowed for a rich data set, even if it
were not possible to adhere to the original specified study protocol time-points.

P a g e | 21

CHAPTER 3: Results
STUDY POPULATION
A total of 120 plasma ribavirin concentrations from 24 lung transplant
recipients, as well as 188 concentration-time data-points extracted from
previously reported data for 6 healthy volunteers, were included in the
population pharmacokinetic analysis. No data-points were excluded from the
dataset. A summary of patient characteristics is included in Table 3.1.

Table 3.1: Participant Characteristics
Data expressed as mean ± standard deviation [range]
St Vincent’s Hospital
Patients

University Medical
Centre Groningen
Patients

Healthy Volunteers

Count

11

13

6

Gender

7 Male / 4 Female

5 Male / 8 Female

6 Male / 0 Female

Age (years)

46.1 ± 14.3 [26 – 63]

53.2 ± 14.4 [27 – 73]

36.8 ± 5.34 [31 – 44]

Body Weight (kg)

65.6 ± 15.6 [47 – 105]

73.2 ± 18.4 [42 – 120]

78.3 ± 11.3 [58.7 – 89.9]

61.8 ± 30.7 [20.1 – 126]

56.6 ± 25.4 [25.1 – 111]

105 ± 13.2 [86.8 – 120

7.39 ± 4.85 [0.25 – 15.1]

4.06 ± 3.06 {0.25 – 7.00]*

N/A

4 Cystic Fibrosis / 4
COPD / 3 Alpha-1
Antitrypsin Deficiency /
1 Pulmonary Fibrosis / 1
Pulmonary
Hypertension

2 Pulmonary
Hypertension, 2 Cystic
Fibrosis / 1 Interstitial
Lung Disease / 1 COPD
/ 5 Unknown

N/A

Creatinine Clearance
(mL/min)
Time since
Transplantation (years)

Underlying Disease

*n=4

No significant differences were found in participant characteristic data, with the
exception of creatinine clearance which was significantly higher in healthy
volunteers compared to the St Vincent’s Hospital and University Medical
Centre Groningen patient groups.

FINAL POPULATION PHARMACOKINETIC MODEL
A three-compartment model with first-order elimination from the central
compartment was found to most adequately describe ribavirin concentrationP a g e | 22

time data. The model incorporated population parameter variability for CL, Vc,
CLd1, CLd2, Ka and F, and proportional residual unexplained variability.
Introduction of covariates into the structural model identified an effect of
creatinine clearance (CrCL, calculated as Cockcroft-Gault equation) on CL, an
effect of body weight (Wt) on Vc (incorporated using allometric scaling), and
patient type (i.e. lung transplant recipient or healthy normal volunteer) on CL
and Vc.
On model diagnostics, the model was found to well characterise the ribavirin
concentration-time data and comparison of observed data and median and 90%
prediction intervals of simulated data demonstrated close prediction over the
time course of the study.
The final population pharmacokinetic model is illustrated in Figure 3.1 and
population parameter estimates of the final pharmacokinetic model are
presented in Table 3.2. A summary of model development and the final model
code is included within Appendix 1.
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Figure 3.1: Schematic of the final ribavirin population pharmacokinetic model
CL, clearance; Vc, volume of distribution of the central compartment; Vp, volume of
distribution of the peripheral compartment; CLd, intercompartmental clearance; Ka,
absorption rate constant; CrCL, creatinine clearnace; CrCL~CL, effect of creatinine
clearance on clearance; Pt, patient type where 0 = healthy control and 1 = lung
transplant recipient; Pt~CL, effect of patient type on clearance; PPV, population
parameter variability.
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Table 3.2: Final Ribavirin Population Pharmacokinetic Model Parameter
Estimates
CL, clearance; Vc, volume of distribution of the central compartment; Vp, volume of
distribution of the peripheral compartment; CLd, intercompartmental clearance; Ka,
absorption rate constant; F, oral bioavailability; CrCL~CL, effect of creatinine clearance
on clearance; Pt~CL, effect of patient type on clearance; PPV, population parameter
variability; %RSE, relative standard error, %CV, coefficient of variation.
Parameter

Final Model: Estimate
(%RSE)

Shrinkage

Eta Bar P

Fixed Effects
CL (L/hr)

17.5 (27.0%)

Vc (L)

52.2 (18.6%)

Vp1 (L)

152 (38.8%)

Vp2 (L)

1140 (21.8%)

CLd1 (L/hr)

40.7 (22.0%)

CLd2 (L/hr)

39.8 (17.5%)

Ka (hr-1)

0.318 (19.8%)

F (%)

0.512 (12.1%)

CrCL~CL

0.574 (64.6%)

Pt~CL

0.586 (33.8%)

Random Effects
PPV CL (%CV)

34.9%

39.5%

0.759

PPV Vc (%CV)

34.1%

51.5%

0.803

PPV CLd1 (%CV)

34.6%

49.9%

0.787

PPV CLd2 (%CV)

49.4%

26.3%

0.842

PPV Ka (%CV)

19.7%

64.3%

0.946

PPV F (%CV)

44.8%

13.8%

0.938

25.7%

9.9%

Residual Variability
Proportional (%CV)
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EXAMINATION OF DOSING REGIMENS
A representative patient population of 10,000 lung transplant recipients with
distributions of creatinine clearance and associated body weights consistent
with that seen within the patient cohort was constructed and concentrationtime profiles simulated using the developed population pharmacokinetic model
to examine the ability of the current and alternate dosing regimens to achieve
target concentrations over a 14-day treatment course. It should be noted that for
oral dosing regimens, doses administered were rounded to the nearest 200 mg
(i.e. tablet size) so that recommended regimens could be administered to
patients using currently available products (200mg tablets being the available
preparation).
Based on the simulations, each of the standard dosing regimens currently used
in practice (11 mg/kg TDS PO or IV + 10 mg/kg BD PO or IV) performed well
to achieve target concentrations within the first 24 hours of dosing; however,
despite the loading dose, steady-state concentrations were not achieved by the
end of the 14-day treatment course (Figure 3.2). Plasma ribavirin concentrations
continued to accumulate over the course of the treatment period such that >90%
of patients are predicted to have concentrations well above the upper limit of
the defined therapeutic range on Day 14. For the median patient, these
concentrations were predicted to be 2- to 3-fold higher than the target
concentrations. Similar results were observed when stratified by renal function,
indicating that the observed drug accumulation was not primarily due to
altered creatinine clearance in a patient subgroup.

P a g e | 26

Figure 3.2: Plasma ribavirin concentration-time profile
Data presented as median solid line and 90% prediction intervals (shaded).
A. 11 mg/kg q8hIV for the first 24 hours, followed by a maintenance dose of 10 mg/kg
q12h IV

B. 11 mg/kg q8h IV for the first 24 hours, followed by a maintenance dose of 10 mg/kg
q12h PO
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C. 11 mg/kg q8h PO for the first 24 hours, followed by a maintenance dose of 10 mg/kg
q12h PO

Alternate dosing regimens were simulated to determine doses predicted to
result in concentrations within the therapeutic range at the end of the treatment
period (Figure 3.3). An oral dosing regimen of 11 mg/kg TDS PO + 4 mg/kg
BD PO (similar to current IV loading dose with ongoing dose reduced by half)
was found to result in plasma ribavirin concentrations for the median patient
between the desired 2.5 – 3 mg/L range, and >90% of patients achieving
concentrations above 1.5 mg/L. However, despite the loading dose achieving
therapeutic targets at the end of Day 1, plasma concentrations declined on Day
2 and then progressively increased by the end of the nominal treatment period.
Consistent results were seen across the spectrum of renal functions. Similar
results were seen for an all oral dosing regimen of 11 mg/kg TDS PO +
8 mg/kg d. PO.
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Figure 3.3: Plasma ribavirin concentration-time profile
Data presented as median solid line and 90% prediction intervals (shaded).
A. 11 mg/kg q8h PO for the first 24 hours, followed by a maintenance dose of 4 mg/kg
q12h PO

B. 11 mg/kg q8h PO for the first 24 hours, followed by a maintenance dose of 8 mg/kg
q24h PO
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An alternate regimen was designed to achieve concentrations in the desired
range at the beginning of treatment and maintain these throughout the
treatment course (Figure 3.4). A regimen of 8 mg/kg QID PO for 48 hours
followed by 8 mg/kg d. PO for the remainder of the treatment period was
predicted to result in >90% of patients exhibiting concentrations within the
defined target range throughout the entire treatment period. Slight drug
accumulation is seen for patients with severe renal impairment (<30 mL/min);
however, concentrations are predicted to remained below that seen for the
dosing regimens currently used in clinical practice.
Figure 3.4: Plasma ribavirin concentration-time profile
Data presented as median solid line and 90% prediction intervals (shaded).
A. 8 mg/kg q6h PO for the first 48 hours, followed by a maintenance dose of 8 mg/kg
q24h PO
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CHAPTER 4: Discussion
Despite the use of ribavirin for the treatment of viral respiratory infections, little
is known in regard to the ability of current dosing regimens to meet effective
target plasma concentrations. This is particularly relevant for the lung
transplant population for which sub-therapeutic treatment is likely to result in
significant morbidity and reduced median survival as a result of BOS. Supratherapeutic doses have been associated with haemolytic anaemia and renal
impairment. Evidence-based dosing regimens are therefore critical for the
[15]

optimal treatment of these patients. This study undertook a population
pharmacokinetic approach to determine the pharmacokinetic properties of
ribavirin and the factors contributing to variability in this patient group. This
then allowed for the examination of current and alternate dosing regimens and
their ability to meet predefined therapeutic targets.
Our population pharmacokinetic analysis confirmed that ribavirin is
characterised by three-compartmental pharmacokinetics, with first order
elimination, consistent with compartmental analysis previously reported and
8

the known pharmacokinetic properties of ribavirin that have been previously
described. The model found total body clearance to be influenced by
[15]

creatinine clearance (with a 10% reduction in CrCL associated with a 6%
reduction in systemic clearance), this is not unexpected given that renal
clearance comprises approximately one-third of total clearance. Patient type
also influenced clearance, with lung transplant recipients exhibiting a 41%
reduction in systemic clearance when compared with healthy controls.
Simulations of current IV and/or PO ribavirin dosing regimens indicate that,
whilst administration of the standard loading doses result in plasma
concentrations within the target therapeutic range early in the treatment course,
concentrations continue to accumulate throughout the 14-day treatment period
such that later concentrations are substantially higher than the defined upper
limit of 4.0 mg/L.

[46,47]

Previous studies indicated that ribavirin concentrations

>3.5 mg/L are associated with severe side effects, even after only a few days of
treatment.

[44-47]

Therefore, it is feasible that these regimens may be associated with

increased risk of adverse effects. On the other hand, alternate dosing regimens
that target effective concentrations at the end of the treatment period are
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predicted to result in sub-therapeutic concentrations during the first days of
treatment, thereby potentially placing patients at risk of ineffective treatment.
Utilising the developed pharmacokinetic model and known characteristics of
ribavirin, this study has been able to propose a dosing regimen, consisting of
8 mg/kg q6h oral for the first 48 hours, followed by a maintenance dose of
8 mg/kg q24h oral, that is predicted to result in early attainment of therapeutic
concentrations and continued maintenance at these levels throughout the
treatment course. Arguably, this indicates that therapeutic levels can be
achieved with a 45% reduction in total dose administered; the combination of
oral administration and dose reduction has potential for substantial cost
savings. Notably, whilst this regimen includes higher loading doses, the
predicted exposure remains below that observed later in the treatment period
for the current regimens and therefore is considered to pose no additional risk
of toxicity.

STUDY STRENGTHS AND WEAKNESSES
Whilst this study provides valuable information on the pharmacokinetics of
ribavirin in the lung transplant population, the majority of patients within this
study were recruited as outpatients and no severe inflammatory states were
seen. As such, the impact of this more complex clinical situation on ribavirin
pharmacokinetics is not able to be determined from this analysis. Furthermore,
due to limited data and/or lacking information for some patients, the influence
of factors, such as underlying disease (including cystic fibrosis), time since
transplantation, or immunosuppressive scheme, could not be determined.
Preliminary examination of the data indicated no discernible trends; however,
full exploration with a larger dataset would be required for definitive
conclusions to be made.
Importantly, it should be noted that current evidence for the proposed
therapeutic target concentrations utilised within this study is limited and
requires additional work. Longitudinal research examining the concentrationadverse effect relationship would be desirable in order to provide more
evidence of the upper limit of ribavirin concentrations that can be tolerated for
short-term therapy and how this relates to what is currently considered “safe”.
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Nonetheless, the developed population pharmacokinetic model provides an
effective tool for anticipating ribavirin exposure in a population with unique
antimicrobial needs. The use of this innovative methodology allows for the
development and examination of optimal treatment regimens without the need
for costly, large-scale clinical trials, providing an evidence basis for effective
treatment protocols.
This study provides a valuable first step in determining optimal ribavirin
treatment regimens for paramyxovirus infections in the lung transplant
population. Results of this work suggest that a regimen of 8 mg/kg QID PO for
48 hours followed by 8 mg/kg daily PO for the remainder of the treatment
period is effective in maintain >90% of patients within the currently defined
target range for the duration of treatment.

CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS
Once the target therapeutic range for ribavirin is formally established, this
study will provide a foundation for ascertaining the safest and most effective
dosing regimen to achieve target plasma concentrations throughout the dosing
interval.
There is a growing body of evidence that plasma concentrations display
heterogeneity between patients, even with identical dosing regimens. A
guideline-recommended course of antimicrobial therapy may result in toxicity
in one patient whilst failing to reach effective concentrations in another.
Guidelines for the “general population” thus do not apply to all patients.
Studies such as the one we have conducted provide important information for
generating appropriate and personalised antimicrobial doses for specific
populations and specific patients. In the future, this research has the potential to
provide the basis for a new era of individualised treatment, with other key
pillars under development being individual genetic and metabolic analysis.
This evolution of treatment has the potential to result in more effective
regimens with reduced mortality, minimisation of the development of
antimicrobial resistance and reduced drug toxicity. It is imperative that more
research is done to identify effective therapeutic concentrations and safety
profiles for optimal treatment and patient outcomes.
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CHAPTER 5: Personal Reflection
There were many setbacks in the execution of this project which led to a delay
in the final submission of our findings to the Journal of Antimicrobial
Chemotherapy. As a developing investigator overcoming these challenges
proved a valuable learning experience in the completion of this Masters project.
Early in the development of the study protocol, funding earmarked from a
hospital trust to provide for a dedicated venepuncture assistant to collect
plasma samples were suddenly unavailable. This led to myself, as the study
investigator, undertaking most of the data collection with some help from
volunteers. Project coordination was thus a greater than expected workload.
Ultimately, this setback had the positive impact of affording the opportunity to
develop skills in complex study coordination with direct involvement in every
step of the process from patient consent to blood collection, sample processing,
data analysis and finally authoring a manuscript for publication. The
experience of juggling a research degree whilst undertaking full-time medical
training program, whilst challenging, was a good way to develop skills in time
management and productivity.

The flexibility of the investigating team proved useful again in mid 2014 when a
manufacturing issue interrupted the supply chain of IV ribavirin to Australia.
Oral stock remained unaffected so patients were given substituted oral loading
doses at the discretion of their treating clinicians. Instead of giving-up on the
work already done, we continued the project and the data collected during this
incident afforded greater opportunity to compare mixed IV/PO versus PO only
regimes. Eventually supply was re-established and the project continued as per
the original study protocol.

Several of the team members working on the initial data collection phase had
personal difficulties during the completion of this project. Unfortunately,
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interpersonal conflict between the other team members also developed. These
incidents became valuable exercises in developing mediation skills to use when
supervising junior staff. Under the guidance of Professor Richard Day (the head
of the St Vincent’s Department of Clinical Pharmacology) we led mediation
sessions in which we developed strategies for individuals in conflict to continue
working together. Moving a project forward through differing expectations,
workloads and standards of professional behaviour was an ongoing challenge
and, I imagine, something that affects all research projects. Nevertheless,
developing the skill of personnel management is an asset to any study
coordinator.

To add an extra challenge but also advantage to our study, project supervisor
Professor Deborah Marriott, developed a partnership with the University
Medical Centre Groningen Transplant Unit in the Netherlands after the initial
data collection phase had begun. Favourably, this professional relationship
doubled our patient cohort. Although of great benefit to the project, this did
add a layer of difficulty due to the demands of coordinating data collection and
analysis between two international centres. Although not easy, collaborating
over great distances is again a useful experience for clinicians as multi-centre
studies are usually of a higher standard and achieve statistical significance
more reliably that single-centre cohorts.
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APPENDIX 1: Population
Pharmacokinetic Model
MODEL DEVELOPMENT
Pharmacokinetic parameters were estimated using non-linear mixed effects
modelling using first-order conditional estimation (FOCE) with interaction. The
population parameter variability (comprising between-subject variability and
between-occasion variability) was modelled using an exponential random effect
model:
θi = θ . exp (ηi)
where: θi is the pharmacokinetic parameter for the ith individual; θ is the
population pharmacokinetic parameter; ηi is a random variable of population
parameter variability which is assumed to be normally distributed around zero
with a variance of ω2 to distinguish the ith patients value from the population
estimate. The population parameter variability was expressed as a coefficient of
variation (%CV, approximated by the square root of the variance estimate).

The residual unexplained variability, arising from such factors as experimental
errors and model misspecification, was modelled with the use of a combined
proportional and additive model:
Cij = Ĉij . (1 + Ɛ1,ij) + Ɛ2,ij
where: Cij is the jth observed concentration for the ith individual; Ĉij is the
corresponding predicted concentration; Ɛ1,ij and Ɛ2,ij are randomly distributed
variables with a mean of zero and variances of σ12 (expressed as %CV) and σ22
(expressed as standard deviation), respectively.

Once the base structural model had been determined, linear regression was
used to screen for associations between each of the individual post-hoc
parameters and available covariates. Various models were then examined
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incorporating effects for covariates identified from linear regression screening.
Continuous covariates were centred on typical values such that population
estimates represent that for an average patient and were incorporated into the
structural model as per that for body weight:
θi = [θ . Weight/70) ^ θ2] . exp (ηi)
where: θi is the pharmacokinetic parameter for the ith individual; θ is the
population pharmacokinetic parameter; θ2 is the effect of the covariate; ηi is the
random effect of population parameter variability.

Categorical covariates were introduced into the structural model as per that for
gender:
θi = [θ . θ2 ^ Gender)] . exp (ηi)
where: θi is the pharmacokinetic parameter for the ith individual; θ is the
population pharmacokinetic parameter; θ2 is the effect of the covariate; ηi is the
random effect of population parameter variability.

After incorporation of all significant covariates into the model, a backward
elimination process was employed to confirm the relevance of each covariate in
the final model.

MODEL DIAGNOSTICS
The adequacy with which the pharmacokinetic model described the
concentration-time data was determined through examination of the precision
of parameter estimates and objective function value. A reduction in the
objective function value by 3.84 for the addition of a single parameter was
considered statistically significant (p<0.05) and representative of improvement.
In conjunction with the objective function value, alternative selection measures,
including Akaike Information Criterion (AIC) and Bayesian Information
Criterion (BIC) were also considered. A reduction in the AIC and/or BIC from
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the initial model to the subsequent model were confirmation of improvement.
The AIC and BIC were defined by the following equations:
AIC = OFV + 2p
BIC = OFV + (p . logN)
where: OFV is the objective function value; p is the number of unknown
parameters (θ, σ2 and ω2) in the model; N is the number of observations.

Model selection was also based on visual inspection of standard diagnostic
plots including observed concentrations versus population predicted and
individual predicted concentrations, and conditional weighted residuals versus
population predicted concentrations and time.

To assess the reliability of the post-hoc individual parameter estimates for
model diagnostics and comparison, the shrinkage of the empirical Bayes
estimates was calculated. In addition, to test the hypothesis that the post-hoc
individual parameters are centred on the population estimate, eta-bar p values
were calculated.

A visual predictive check was used to characterise the performance of the final
model. The parameter estimates, population parameter variability and residual
unexplained variability were used to generate 1000 simulated datasets from
which median and 90% prediction intervals (5th and 95th percentiles) of the
simulated values were determined and compared to observed values.

FINAL POPULATION MODEL
Model development is outlined in Table A1.1. The effects of covariates on
random effects are presented in Figure A1.1.

The diagnostic plot of individual predicted concentrations versus observed
concentrations was symmetrically distributed around the line of unity and no
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trends were observed in the conditional weighted residuals diagnostic plots,
indicating that the model adequately describes the ribavirin pharmacokinetic
profile (Figure A1.2).

The control stream for the final population pharmacokinetic model is presented
in Appendix A1.1.
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Table A1.1: Summary of Model Development
PPV, population parameter variability; Vp, volume of distribution of the peripheral
compartment; CrCL~CL, effect of creatinine clearance on clearance; Wt~Vc, effect of
weight on central volume of distribution; Pt~CL, effect of patient type on clearance;
Pt~Vc, effect of patient type on central volume of distribution; ΔOFV, change in
objective function value; ΔAIC, change in Akaike Information Criterion; ΔBIC, change
in Bayesian Information Criterion.
Model ID

Model Description

Model Comparison

Structural Model Development
RBVPopPKModel01

1 compartment

RBVPopPKModel02

2 compartment

c.f. RBVPopPKModel01
ΔOFV: -373.96 ΔAIC: -365.27 ΔBIC: 350.35

RBVPopPKModel03

3 compartment

c.f. RBVPopPKModel02
ΔOFV: -42.97 ΔAIC: -34.04 ΔBIC: -19.12

RBVPopPKModel04

RBVPopPKModel03 + Transit

c.f. RBVPopPKModel03
ΔOFV: 17.21 ΔAIC: 17.21 ΔBIC: 17.21

RBVPopPKModel05

RBVPopPKModel04 – Additive Error

c.f. RBVPopPKModel03
ΔOFV: -0.75 ΔAIC: -3.01 ΔBIC: -6.74

RBVPopPKModel06

RBVPopPKModel05 – PPVVp1

c.f. RBVPopPKModel05
ΔOFV: 0.38 ΔAIC: -1.86 ΔBIC: -5.59

RBVPopPKModel07

RBVPopPKModel06 – PPVVp2

c.f. RBVPopPKModel06
ΔOFV: 0 ΔAIC: -2.23 ΔBIC: -5.96

RBVPopPKModel08

RBVPopPKModel07 + Covariance

c.f. RBVPopPKModel07

Matrix

ΔOFV: -38.22 ΔAIC: -3.15 ΔBIC: 52.8

Full (Covariate) Model Development
RBVPopPKModel09

RBVPopPKModel07 + CrCL~CL

c.f. RBVPopPKModel07
ΔOFV: -8.98 ΔAIC: -6.75 ΔBIC: -3.02

RBVPopPKModel10

RBVPopPKModel09 + Wt~V2

c.f. RBVPopPKModel09
ΔOFV: -0.03 ΔAIC: 2.21 ΔBIC: 5.94

RBVPopPKModel11

RBVPopPKModel09 + Pt~CL

c.f. RBVPopPKModel09
ΔOFV: -2.92 ΔAIC: -0.68 ΔBIC: 3.05

RBVPopPKModel12

RBVPopPKModelPK11 + Pt~V2

c.f. RBVPopPKModel11
ΔOFV: -1.98 ΔAIC: 0.28 ΔBIC: 4.01

RBVPopPKModel13

RBVPopPKModel11 – CRCL~CL

c.f. RBVPopPKModel11
ΔOFV: 3.48 ΔAIC: 1.24 ΔBIC: -2.49
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Figure A1.1: Effect of the Introduction of Covariates on Random Effects (ETA).
A. Random effect for clearance (CL) versus creatinine clearance (CrCL) obtained from
the base structural model and after the introduction of CrCL as a covariate on CL.

B. Random effect for clearance (CL) versus patient type (Pt) obtained from the base
structural model and after the introduction of Pt as a covariate on CL.
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Figure A1.2: Final Population Pharmacokinetic Model Diagnostic Plots.
A. Population predicted concentration versus observed concentration, including line of
unity (black line) and line of best fit (red line).

B. Individual predicted concentration versus observed concentration, including line of
unity (black line) and line of best fit (red line).
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C. Conditional weighted residuals versus observed concentration, including zero line
(black line) and line of best fit (red line).

D. Conditional weighted residuals versus time, including zero line (black line) and line
of best fit (red line).
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Appendix A1.1 – Model Code
$PROBLEM

Ribavirin PK in Lung Transplant

$DATA

Data.csv

$INPUT

ID TIME AMT RATE DV MDV EVID CMT PT SEX AGE WT HT SCR IBW CRCL

$SUBROUTINES

ADVAN6 TOL=9

$MODEL

NCOMPARTMENTS=4
COMP=(DEPOT)
COMP=(CENTRAL,DEFOBS)
COMP=(PERIPH1)
COMP=(PERIPH2)

$PK

POPCL

=

THETA(1)

POPV2

=

THETA(2)

POPV3

=

THETA(3)

POPV4

=

THETA(4)

POPQ1

=

THETA(5)

POPQ2

=

THETA(6)

POPKA

=

THETA(7)

POPF1

=

THETA(8)

CRCL_CL =

THETA(9)

PT_CL

=

THETA(10)

PPVCL

=

ETA(1)

PPVV2

=

ETA(2)

PPVQ1

=

ETA(3)

PPVQ2

=

ETA(4)

PPVKA

=

ETA(5)

PPVF1

=

ETA(6)

CL

=

POPCL*((CRCL/120)**CRCL_CL)*(PT_CL**PT)*EXP(PPVCL)

V2

=

POPV2*EXP(PPVV2)

V3

=

POPV3

V4

=

POPV4

Q1

=

POPQ1*EXP(PPVQ1)

Q2

=

POPQ2*EXP(PPVQ2)

KA

=

POPKA*EXP(PPVKA)

F1

=

POPF1*EXP(PPVF1)

S2

=

V2

$DES

C2

=

A(2)/V2

C3

=

A(3)/V3

C4

=

A(4)/V4

DADT(1) = -A(1)*KA
DADT(2) =

A(1)*KA -C2*Q1 + C3*Q1 -C2*Q2 + C4*Q2 -C2*CL

DADT(3) =

C2*Q1 - C3*Q1

DADT(4) =

$THETA

C2*Q2 - C4*Q2

(0,17.5,)

;POPCL

(0,52.2,)

;POPV2

(0,152,)

;POPV3

(0,1140,)

;POPV4

(0,40.7,)

;POPQ1

(0,39.8,)

;POPQ2

(0,0.318,)

;POPKA

(0,0.512,1)

;POPF1

(-INF,0.574,)

;CRCL_CL

(0,0.586,)

;PT_CL

0.1218

;PPVCL

0.1163

;PPVV2

0.1197

;PPVQ1

0.2440

;PPVQ2

0.0388

;PPVKA

0.2007

;PPVF1

$SIGMA

0.0660

;ERRPROP

$ERROR

Y

$OMEGA

=

IPRED

$ESTIMATION

F*(1+ERR(1))
=

METHOD=1

F

INTERACTION

MAXEVALS=9999 POSTHOC

NOABORT

NSIG=3 SIGL=9
$COVARIANCE

UNCONDITIONAL SLOW SIGL=12 PRINT=E

$TABLE

ID TIME AMT RATE CL V2 V3 V4 Q1 Q2 KA F1 ETA1 ETA2 ETA3 ETA4
ETA5 ETA6 IPRED CWRES PT SEX AGE WT HT SCR IBW CRCL NOPRINT
ONEHEADER FILE=
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APPENDIX 2: Publications
MANUSCRIPT
Milliken E, de Zwart AES, Alffenaar JC, Marriott DJE, Riezebos-Brilman A,
Schteinman A, Evans AM, Glanville AR, Verschuuren EAM, Reuter SE.
Population pharmacokinetics of ribavirin in lung transplant recipients and
examination of current and alternative dosing regimens. J Antimicrob
Chemother; DOI 10.1093/jac/dky466 [Epub ahead of print]
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CONFERENCE PRESENTATIONS
Milliken E, Marriott D, Schteinman A, de Zwart A, Sandaradura I, Carlos L,
Burrows F, Glanville A, Reuter SE. A predictive pharmacokinetic model of
ribavirin plasma concentration in lung transplant recipients [Poster
Presentation]. International Congress of the Transplantation Society (TTS),
August 2016: Hong Kong.
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Abstract
Ribavirin is a guanosine analogue used for treatment of respiratory syncytial
virus (RSV) pneumonitis in vulnerable populations, and is standard of care
for RSV in global lung transplant centres to prevent acute pneumonitis and
bronchiolitis obliterans syndrome. Despite this, the pharmacokinetic profile
of ribavirin in the transplant population is unknown and is likely to be
altered due to immunosuppressant regimens, renal and hepatic impairment
and cystic fibrosis in affected individuals. At St Vincent’s Hospital, the
empirically-determined treatment protocol for ribavirin in lung transplant
patients is three initial IV loading doses (11mg/kg tds) followed by
maintenance dosing with oral ribavirin (10mg/kg bd); however, whilst the
treatment protocol has demonstrated efficacy, the ribavirin exposure for the
two treatment formulations has not been established. To examine the
pharmacokinetics of oral and IV ribavirin in the lung transplant population,
a prospective, single-centre cohort study was conducted. Twelve lung
transplant patients with PCR-confirmed RSV or HMPV infection were
recruited for study participation (7 male/5 female; Age: 45.3 ± 13.9 years;
BMI: 23.8 ± 4.82 kg/m2; CrCL: 69.2 ± 26.7mL/min). Patients were administered
ribavirin according to the standard hospital protocol, and blood samples
were collected throughout the IV and oral treatment periods. Plasma
ribavirin concentrations were quantified using a validated HPLC-UV
analytical method. Patient concentration-time data, combined with
previously published ribavirin pharmacokinetic data, were used to develop a
population pharmacokinetic model, using NONMEM® VII software,
incorporating inter-individual and residual unexplained variability. Patient
factors contributing to parameter variability (such as renal function, patient
status, body weight) were modelled using standard forwardinclusion/backward-deletion methods. Model selection was based on the
objective function value and standard diagnostic plots. The developed model
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was then used to conduct Monte Carlo simulations examine alternate dosing
regimens, in particular if comparable drug exposure can be achieved with
oral only dosing regimens as opposed to mixed regimens, thereby reducing
patient bed days and increasing convenience. Additional research is needed
to establish effective plasma ribavirin concentrations for viral eradication;
however, it is anticipated that the developed pharmacokinetic model will
allow predictions of optimal dosing regimens to meet therapeutic
pharmacokinetic/pharmacodynamic endpoints as more is learned about
effective treatment of respiratory viruses in lung transplant patients.
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Abstract
The guanosine analogue ribavirin (RBV) is an established treatment for
respiratory viruses in lung transplant recipients. [1-5]. Goals of treatment are
prevention of progression of lower respiratory tract viral infection to deadly
pneumonitis as well as prevention of the bronchiolitis obliterans syndrome,
linked with progressive deterioration of graft function [5-7]. Despite RBV’s
common usage, pharmacokinetic data is limited and the difference in relative
exposure between oral and intravenous regiments, both of which are used at
transplant centres internationally, is unknown. To address this the authors
developed a physiological pharmacokinetic model of RBV in the transplant
population using data collected from a cohort of lung transplant recipients
being treated with RBV for respiratory syncytial virus (RSV), human
metapneumovirus (HMPV) or parainfluenza virus infection. Data was
collected at St Vincent’s Hospital Sydney and Groningen University Medical
Centre, Netherlands. The model was validated using published data from
healthy volunteers [8]. Our model established that there is no difference in
the pharmacokinetics of RBV in lung transplant recipients in comparison to
the general population. It also support PO only regimes for a desired plasma
concentration of 1.5-3.0 µg/mL as well as providing a valuable tool for
predicting effective dosing in this vulnerable population.
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Abstract
Introduction. Ribavirin is used in the treatment of respiratory paramyxovirus
infection in lung transplant recipients; however, its pharmacokinetic profile
in the transplant population is unknown despite the potential for alterations
due to underlying pathology. Furthermore, the ability of current regimens to
meet exposure targets has not been established. Aim. This study examined
the pharmacokinetics of ribavirin in a lung transplant population from which
current and alternate dosing regimens were assessed. Methods. Population
pharmacokinetic modelling was conducted in NONMEM using
concentration-time data from 24 lung transplant recipients and 6 healthy
volunteers. Monte Carlo simulation was used to assess the ability of dosing
regimens to achieve pre-specified target concentrations. Results and
Conclusions. A three-compartment model with first order elimination most
adequately described ribavirin concentration-time data, with creatinine
clearance and patient type (i.e. lung transplant) identified as significant
covariates in the model. Simulations indicate that current regimens achieve
efficacious concentrations within 24 hours of treatment initiation that
increase to supra-therapeutic levels over the treatment period. A regimen of
8 mg/kg q6h oral for 48 hours followed by 8 mg/kg q24h oral for the
remainder of the treatment period was predicted to result in >90% of patients
exhibiting concentrations within the defined target range throughout the
entire treatment course. Additional work to formally establish of target
therapeutic concentrations is required; however, this study provides a
valuable first step in determining optimal ribavirin treatment regimens for
paramyxovirus infections in the lung transplant population.
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